Literature DB >> 22848234

Protease-activated receptors in cancer: A systematic review.

Na Han1, Ketao Jin, Kuifeng He, Jiang Cao, Lisong Teng.   

Abstract

The traditional view of the role of proteases in tumor growth, progression and metastasis has significantly changed. Apart from their contribution to cancer progression, it is evident that a subclass of proteases, such as thrombin, serves as signal molecules controlling cell functions through the protease-activated receptors (PARs). Among the four types of PAR (PAR1-4; cloned and named in order of their discovery), PAR1, PAR3 and PAR4 are activated by thrombin, unlike PAR2, which is activated by trypsin-like serine proteases. Thrombin has been proven to be a significant factor in both the behavior of cancer in its involvement in hemostasis and blood coagulation. Thrombin is a key supporter of various cellular effects relevant to tumor growth and metastasis, as well as a potent activator of angiogenesis, which is essential for the growth and development of all solid tumor types. This review presents an overview of the role of PAR-mediated thrombin in angiogenesis and cancer, focusing on the ability of PAR1- and PAR4-mediated thrombin to affect tumorigenesis and angiogenesis.

Entities:  

Year:  2011        PMID: 22848234      PMCID: PMC3406414          DOI: 10.3892/ol.2011.291

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  157 in total

1.  Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo.

Authors:  M L Nierodzik; F Kajumo; S Karpatkin
Journal:  Cancer Res       Date:  1992-06-15       Impact factor: 12.701

2.  Structure-function analysis of protease-activated receptor 4 tethered ligand peptides. Determinants of specificity and utility in assays of receptor function.

Authors:  T R Faruqi; E J Weiss; M J Shapiro; W Huang; S R Coughlin
Journal:  J Biol Chem       Date:  2000-06-30       Impact factor: 5.157

3.  Proteinase-activated receptor 4 (PAR4): activation and inhibition of rat platelet aggregation by PAR4-derived peptides.

Authors:  M D Hollenberg; M Saifeddine
Journal:  Can J Physiol Pharmacol       Date:  2001-05       Impact factor: 2.273

Review 4.  Angiogenesis research: guidelines for translation to clinical application.

Authors:  J Folkman; T Browder; J Palmblad
Journal:  Thromb Haemost       Date:  2001-07       Impact factor: 5.249

5.  Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4.

Authors:  Roland Kaufmann; Stephanie Rahn; Kristin Pollrich; Julia Hertel; Yves Dittmar; Merten Hommann; Peter Henklein; Christoph Biskup; Martin Westermann; Morley D Hollenberg; Utz Settmacher
Journal:  J Cell Physiol       Date:  2007-06       Impact factor: 6.384

6.  Protease-activated receptor 3 is a second thrombin receptor in humans.

Authors:  H Ishihara; A J Connolly; D Zeng; M L Kahn; Y W Zheng; C Timmons; T Tram; S R Coughlin
Journal:  Nature       Date:  1997-04-03       Impact factor: 49.962

7.  Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig.

Authors:  Yasuko Kato; Yasuhiro Kita; Yoshimi Hirasawa-Taniyama; Mie Nishio; Kayoko Mihara; Kiyotaka Ito; Toshio Yamanaka; Jiro Seki; Susumu Miyata; Seitaro Mutoh
Journal:  Eur J Pharmacol       Date:  2003-07-25       Impact factor: 4.432

8.  A murine monoclonal antibody that binds N-terminal extracellular segment of human protease-activated receptor-4.

Authors:  Takeshi Sangawa; Terukazu Nogi; Junichi Takagi
Journal:  Hybridoma (Larchmt)       Date:  2008-10

Review 9.  Current anticoagulant therapy--unmet clinical needs.

Authors:  Jack Hirsh
Journal:  Thromb Res       Date:  2003-07-15       Impact factor: 3.944

10.  Requirement of vascular integrin alpha v beta 3 for angiogenesis.

Authors:  P C Brooks; R A Clark; D A Cheresh
Journal:  Science       Date:  1994-04-22       Impact factor: 47.728

View more
  16 in total

1.  Platelet-mediated angiogenesis is independent of VEGF and fully inhibited by aspirin.

Authors:  J Etulain; C Fondevila; S Negrotto; M Schattner
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

2.  MALT1 is a critical mediator of PAR1-driven NF-κB activation and metastasis in multiple tumor types.

Authors:  Peter C Lucas; Linda M McAllister-Lucas; J Randall McAuley; Kelly M Bailey; Prasanna Ekambaram; Linda R Klei; Heejae Kang; Dong Hu; Tanner J Freeman; Vincent J Concel; Nathaniel E Hubel; Jia-Ying Lloyd Lee; Hanna B Klei; Jing Cheng; Preethiya Sekar; Rachel E Bridwell; Lidija Covic
Journal:  Oncogene       Date:  2019-08-16       Impact factor: 9.867

3.  Protease-activated receptor (PAR)1, PAR2 and PAR4 expressions in esophageal squamous cell carcinoma.

Authors:  Si-Man Li; Ping Jiang; Yang Xiang; Wei-Wei Wang; Yue-Chun Zhu; Wei-Yang Feng; Shu-De Li; Guo-Yu Yu
Journal:  Dongwuxue Yanjiu       Date:  2014-09

4.  Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score.

Authors:  Guido Marcucci; Pearlly Yan; Kati Maharry; David Frankhouser; Deedra Nicolet; Klaus H Metzeler; Jessica Kohlschmidt; Krzysztof Mrózek; Yue-Zhong Wu; Donna Bucci; John P Curfman; Susan P Whitman; Ann-Kathrin Eisfeld; Jason H Mendler; Sebastian Schwind; Heiko Becker; Constance Bär; Andrew J Carroll; Maria R Baer; Meir Wetzler; Thomas H Carter; Bayard L Powell; Jonathan E Kolitz; John C Byrd; Christoph Plass; Ramiro Garzon; Michael A Caligiuri; Richard M Stone; Stefano Volinia; Ralf Bundschuh; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2013-12-30       Impact factor: 44.544

5.  CCL2 at the crossroad of cancer metastasis.

Authors:  Robert Eferl
Journal:  JAKSTAT       Date:  2013-04-01

6.  Doxycycline inhibits breast cancer EMT and metastasis through PAR-1/NF-κB/miR-17/E-cadherin pathway.

Authors:  Weilong Zhong; Shuang Chen; Yuan Qin; Heng Zhang; Hongzhi Wang; Jing Meng; Longcong Huai; Qiang Zhang; Tingting Yin; Yueyang Lei; Jingxia Han; Lingfei He; Bo Sun; Huijuan Liu; Yanrong Liu; Honggang Zhou; Tao Sun; Cheng Yang
Journal:  Oncotarget       Date:  2017-08-24

Review 7.  Protease Inhibitors in Tick Saliva: The Role of Serpins and Cystatins in Tick-host-Pathogen Interaction.

Authors:  Jindřich Chmelař; Jan Kotál; Helena Langhansová; Michail Kotsyfakis
Journal:  Front Cell Infect Microbiol       Date:  2017-05-29       Impact factor: 5.293

8.  PAR1 signaling on tumor cells limits tumor growth by maintaining a mesenchymal phenotype in pancreatic cancer.

Authors:  Maarten F Bijlsma; C Arnold Spek; Cansu Tekin; Kun Shi; Joost B Daalhuisen; Marieke S Ten Brink
Journal:  Oncotarget       Date:  2018-08-10

9.  Kallikrein-related peptidase 4 induces cancer-associated fibroblast features in prostate-derived stromal cells.

Authors:  Thomas Kryza; Lakmali M Silva; Nathalie Bock; Ruth A Fuhrman-Luck; Carson R Stephens; Jin Gao; Hema Samaratunga; Mitchell G Lawrence; John D Hooper; Ying Dong; Gail P Risbridger; Judith A Clements
Journal:  Mol Oncol       Date:  2017-08-10       Impact factor: 6.603

10.  B-cell clonogenic activity of HIV-1 p17 variants is driven by PAR1-mediated EGF transactivation.

Authors:  Cinzia Giagulli; Francesca Caccuri; Simone Zorzan; Antonella Bugatti; Alberto Zani; Federica Filippini; Ekta Manocha; Pasqualina D'Ursi; Alessandro Orro; Riccardo Dolcetti; Arnaldo Caruso
Journal:  Cancer Gene Ther       Date:  2020-10-22       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.